aTyr Pharma, Inc. Common Stock —— 图表、价格与新闻 (NASDAQ:ATYR)

展开完整图表

Financials

概览声明统计

每季度年度

Market Capitalization 82.4513 M
Employee 58
Founded 2005
CEO N/A
Website www.atyrpharma.com
Headquarter Delaware, United States
FIGI BBG001J2P692
Industry Technology

总收入

净利润

每股基本收益（基本 EPS）

总债务

自由现金流

现金及现金等价物

82.45 M 市值

市盈率

-0.98

市销率

383.25

aTyr Pharma Inc

aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.